home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2846.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
4KB
|
55 lines
Document 2846
DOCN M94A2846
TI Antiviral combined and thymostimulin in patients with HIV stages III and
IV. Effects on the CD4 cells counts.
DT 9412
AU Conde-Mercado JM; Feregrino Goyos M; Eid Lidt G; Torras GV; Gallegos
Perez H; Alvarado Diez D; Clinica isi de Norteamerica, Mexico D.F.
Mexico.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):211 (abstract no. PB0273). Unique
Identifier : AIDSLINE ICA10/94369729
AB OBJECTIVES: We tried to evaluate the immunomodulating effects of the TP1
((Thymostimulin derived from calf thymus) in HIV patients with less than
300 CD4 cells, associating the combination of AZT + DDC or AZT + DDC +
NAC. METHODS: We studied 15 patients. They received 50 mg IM daily of
thymostimulin over a period of 120 days. All the patients received 500
mg of AZT and 2.25 mg of DDC and 5 of them 1500 mg of N-acetylcysteine
orally simultaneously. We compared results with a control group of 100
patients who received only AZT + DDC. and formed the Group II. The group
I with thymostimulin was formed by 15 patients, 5 with more than 100 CD4
(average 151), and 10 with less of 100 CD4 cells.. All the patients had
a counts of total lymphocytes, CD4, CD8 and antigen p 24 on a monthly
basis. RESULTS: Patients of the control group (Group II) had a gradual
increases of CD4 of 12, 24 and 35% above basal number with an average of
170 CD4 on day 0. The number of lymphocytes, and CD8 has slightly
increase, and p24 antigens did not modify significantly. In the Group
IA, we observed increases of CD4 from a basal average of 152 to 175, 225
and 285 with increases of 80%. (p < 0.05). In the group IB with less
than 100 CD4 basal count with average of 54 they had increase less
significantly than group IA, without modification in 2 patients with
less than 20 CD4. In the others 8 patients the increase was 54, 66, 77
and 85 CD4 cells (+57%). Lymphocytes CD8 and total increase in average
of 75% in both groups. We did not observe modification in the p 24
antigen level. CONCLUSIONS: Thymostimulin can improve results of
combined antiviral therapy with AZT + DDC in patients with more than 20
CD4. The responses is more significantly in patients with more than 100
CD4.
DE Acetylcysteine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ THERAPEUTIC USE
Acquired Immunodeficiency Syndrome/DRUG THERAPY/THERAPY Adjuvants,
Immunologic/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ *THERAPEUTIC USE
Antiviral Agents/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ *THERAPEUTIC
USE Biological Response Modifiers/ADMINISTRATION & DOSAGE/ADVERSE
EFFECTS/*THERAPEUTIC USE Combined Modality Therapy Comparative Study
Drug Therapy, Combination Human HIV Core Protein p24/BLOOD HIV
Infections/DRUG THERAPY/*THERAPY Interferon Inducers/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS/ *THERAPEUTIC USE Leukocyte Count/*DRUG EFFECTS
Thymus Extracts/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ *THERAPEUTIC
USE Treatment Outcome *T4 Lymphocytes Zalcitabine/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS/THERAPEUTIC USE Zidovudine/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS/THERAPEUTIC USE CLINICAL TRIAL MEETING
ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).